Litcius/Paper detail

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux‐Roels, Paul Willems, Gwenn Waerlop, Yorick Janssens, Jessika Tourneur, Fien De Boever, Jacques Bruhwyler, Azhar Alhatemi, Bart Jacobs, Florence Nicolas, Geert Leroux‐Roels, Alexandre Le Vert

2023The Lancet Infectious Diseases22 citationsDOIOpen Access PDF

Topics & Concepts

ELISPOTMedicineImmunogenicityPlaceboPopulationInfluenza vaccineImmunologyCohortPeripheral blood mononuclear cellInternal medicineImmune systemVirologyVaccinationT cellBiologyPathologyBiochemistryEnvironmental healthAlternative medicineIn vitroInfluenza Virus Research StudiesImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial | Litcius